West Pharma (WST) Misses Q3 EPS by 10c; Offers FY22 Revenue Guidance

West Pharma (NYSE: WST) reported Q3 EPS of $2.03, $0.10 worse than the analyst estimate of $2.13. Revenue for the quarter came in at $686.9 million versus the consensus estimate of $728.11 million.

GUIDANCE:

West Pharma sees FY2022 revenue of $2.83-2.84 billion, versus the consensus of $2.98 billion.

For earnings history and earnings-related data on West Pharma (WST) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• AXT appoints Tracy Liu to its board of directors
• C.H. Robinson acquires DeSpir Logistics for $75 million